Continue

Esc 2016 قصور القلب التوجيهي pptx

Lower NOAC Doses Used Despite Lack of Data PERTs Improve Response and Management of Massive PE Requiem for IVC Filters: Not so Fast When Should Patients With AF Undergo Ablation? Open-Data Movement: Share and Share Alike? Cardiovascular Innovation: Dying or Thriving? AFib Guideline and Cardio-Oncology Expert Consensus Statement at ESC Highlights of the Updated European Dyslipidemia Guidelines New Guidelines Recommend NOACs to Prevent VTE CE-MARC 2: Lowering Unnecessary Angiography Rates With CMR When Not in Rome: Is It OK to Skip Scientific Conferences? Low LDL-C and SBP Sans Drugs Shows CVD Largely Preventable DANISH Details: ICD Use in Nonischemic HF STICH at 10 Years: CABG for Young and Old With Systolic HF? New ESC Guidelines for Heart Failure - what patients need to know Learn more Increase text size Decrease text size Print this page Email this page 2021 AN ANIMATED تحتوي الموضوعات المدرجة في هذه الوثيقة على روابط ستوجه القارئ المهتم إلى الأقسام المناسبة في المبادئ التوجيهية للممارسات السريرية للجمعية الأوروبية ن تكون دليلاً حول كيفية عمل القلب، ولا يمكن أن تكون وافية. JOURNEY THROUGH HEART FAILURE A series of 9 simple, captivating animations explaining heart failure and its treatment. These narrated animations explain how a healthy heart works, what happens to it in heart failure and how various treatments work to improve your health. قصور القلب؟ كيف تعمل الأجهزة الطبية في قصور القلب listen or read interviews with other people with heart failure and their caregivers. What strategy did you use to understand Heart failure and how to live with it? What is self-care? And what can you do to improve your daily basis with heart failure? مريضة في جلسة تمرين What would you like to say to healthcare professionals about the importance of quality of life? How the ESC Patients Guidelines can improve decision making? How did your role as patient representative helped you with your diagnosis? مريضة تستخدم جهاز مزيل الرجفان ومقوّم النظم المزروع (ICD) التعايش مع جهاز مساعدة البطين الأيسر and pregnancy جهاز مساعدة البطين الأيسر مرحلة انتقالية قبل زرع القلب direction of the Heart Failure Association of the European Society of Cardiology (ESC). The ESC is a world leader in the discovery and dissemination of best practices in cardiovascular medicine. Our members and decision-makers are healthcare professionals who volunteer their time and expertise to represent professionals in the field of cardiology in Europe and beyond. 1. ESC GUIDELINES 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chairperson) (The Netherlands), Stefan D. Anker (Germany), He´ctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK), Volkmar Falk (Germany), Jose´ Ramo´n Gonza´lez-Juanatey (Spain), Veli-Pekka Harjola (Finland), Ewa A. Jankowska (Poland), Mariell Jessup (USA), Cecilia Linde (Sweden), Petros Nihoyannopoulos (UK), John T. Parissis (Greece), Burkert Pieske (Germany), Jillian P. Riley (UK), Giuseppe M. C. Rosano (UK/Italy), Luis M. Ruilope (Spain), Frank Ruschitzka (Switzerland), Frans H. Rutten (The Netherlands), Peter van der Meer (The Netherlands) Document Reviewers: Gerasimos Filippatos (CPG Review Coordinator) (Greece), John J. V. McMurray (CPG Review Coordinator) (UK), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Nawwar Al-Attar (UK), John James Atherton (Australia), Johann Bauersachs (Germany), A. John Camm (UK), Scipione Carerj (Italy), Claudio Ceconi (Italy), Antonio Coca (Spain), Perry Elliott (UK), Çetin Erol (Turkey), Justin Ezekowitz (Canada), Covadonga Ferna´ndez-Golfı´n (Spain), Donna Fitzsimons (UK), Marco Guazzi (Italy), * Corresponding authors: Piotr Ponikowski, Department of Heart Diseases, Wroclaw Medical University, Centre for Heart Diseases, Military Hospital, ul. Weigla 5, 50-981 Wroclaw, Poland, Tel: +48 261 660 279, Tel/Fax: +48 261 660 237, E-mail: piotrponikowski@4wsk.pl. Adriaan Voors, Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, The Netherlands, Tel: +31 50 3612355, Fax: +31 50 3614391, E-mail: a.a.voors@umcg.nl. ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers: listed in the Appendix. ESC entities having participated in the development of this document: Associations: Acute Cardiovascular Care Association (ACCA), European Association for Cardiovascular Prevention and Rehabilitation (EACPR), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA). Councils: Council on Cardiovascular Nursing and Allied Professions, Council for Cardiology Practice, Council on Cardiovascular Primary Care, Council on Hypertension. Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases, Myocardial Function, Pulmonary Circulation and Right Ventricular Function, Valvular Heart Disease. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com). Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recom- mendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encour- aged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The article has been co-published with permission in European Heart Journal and European Journal of Heart Failure. All rights reserved in respect of European Heart Journal. & European Society of Cardiology 2016. All rights reserved. For permissions please email: journals.permissions@oup.com. European Heart Journal doi:10.1093/eurheartj/ehw128 European Heart Journal Advance Access published May 20, 2016 byguestonMay22,2016 2. Maxime Guenoun (France), Gerd Hasenfuss (Germany), Gerhard Hindricks (Germany), Arno W. Hoes (The Netherlands), Bernard Iung (France), Tiny Jaarsma (Sweden), Paulus Kirchhof (UK/Germany), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Stavros Konstantinides (Germany/Greece), Mitja Lainscak (Slovenia), Patrizio Lancellotti (Belgium), Gregory Y. H. Lip (UK), Francesco Maisano (Switzerland), Christian Mueller (Switzerland), Mark C. Petrie (UK), Massimo F. Piepoli (Italy), Silvia G. Priori (Italy), Adam Torbicki (Poland), Hiroyuki Tsutsui (Japan), Dirk J. van Veldhuisen (The Netherlands), Stephan Windecker (Switzerland), Clyde Yancy (USA), Jose Luis Zamorano (Spain) The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website . -- Keywords Guidelines † Heart failure † Natriuretic peptides † Ejection fraction † Diagnosis † Pharmacotherapy † Neuro-hormonal antagonists † Cardiac resynchronization therapy † Mechanical circulatory support † Transplantation † Arrhythmias † Co-morbidities † Hospitalization † Multidisciplinary management

Table of Contents

Abbreviations and acronyms . . . . 3 1. Preamble . . . . 7 2. Introduction . . . . 8 3. Definition, epidemiology and prognosis . . . . 8 3.1 Definition of heart failure . . . . 8 3.2 Terminology . . . . 9 3.2.1 Heart failure with preserved, mid-range and reduced ejection fraction . . . . 9 3.2.2 Terminology related to the time course of heart failure . . . . 9 3.2.3 Terminology related to the symptomatic severity of heart failure . . . . 10 3.3 Epidemiology, aetiology and natural history of heart failure 10 3.4 Prognosis . . . . 10 4. Diagnosis . . . . 10 4.1 Symptoms and signs . . . . 10 4.2 Essential initial investigations: natriuretic peptides, electrocardiogram, and echocardiography . . . . 11 4.3 Algorithm for the diagnosis of heart failure . . . . 12 4.3.1 Algorithm for the diagnosis of heart failure in the non-acute setting . . . . 12 4.3.2 Diagnosis of heart failure with preserved ejection fraction . . . . 12 5. Cardiac imaging and other diagnostic tests . . . . 14 5.1 Chest X-ray . . . . 14 5.2 Transthoracic echocardiography . . . . 14 5.2.1 Assessment of left ventricular systolic function . . . . 14 5.2.2 Assessment of left ventricular diastolic function . . . 15 5.2.3 Assessment of right ventricular function and pulmonary arterial pressure . . . . 15 5.3 Transoesophageal echocardiography . . . . 15 5.4 Stress echocardiography . . . . 15 5.5 Cardiac magnetic resonance . . . . 15 5.6 Single-photon emission computed tomography and radionuclide ventriculography . . . . 15 5.7 Positron emission tomography . . . . 15 5.8 Coronary angiography . . . . 16 5.9 Cardiac computed tomography . . . . 16 5.10 Other diagnostic tests . . . . 17 5.10.1 Genetic testing in heart failure . . . . 17 6. Delaying or preventing the development of overt heart failure or preventing death before the onset of symptoms . . . . . 18 7. Pharmacological treatment of heart failure with reduced ejection fraction . . . . 19 7.1 Objectives in the management of heart failure . . . . 19 7.2 Treatments recommended in all symptomatic patients with heart failure with reduced ejection fraction . . . . 20 7.2.1 Angiotensin-converting enzyme inhibitors . . . . 20 7.2.2 Beta-blockers . . . . 20 7.2.3 Mineralocorticoid/aldosterone receptor antagonists . 20 7.3 Other treatments recommended in selected symptomatic patients with heart failure with reduced ejection fraction . . . 20 7.3.1 Diuretics . . . . 20 7.3.2 Angiotensin receptor neprilysin inhibitor . . . . 23 7.3.3 If -channel inhibitor . . . . 24 7.3.4 Angiotensin II type I receptor blockers . . . . 24 7.3.5 Combination of hydralazine and isosorbide dinitrate . . . . 24 7.4 Other treatments with less certain benefits in symptomatic patients with heart failure with reduced ejection fraction . . . . 24 7.4.1 Digoxin and other digitalis glycosides . . . . 24 7.4.2 n-3 polyunsaturated fatty acids . . . . 25 7.5 Treatments not recommended (unproven benefit) in symptomatic patients with heart failure with reduced ejection fraction . . . . 25 7.5.1 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ('statins') . . . . 25 7.5.2 Oral anticoagulants and antiplatelet therapy . . . . . . 25 7.5.3 Renin inhibitors . . . . 25 7.6 Treatments not recommended (believed to cause harm) in symptomatic patients with heart failure with reduced ejection fraction . . . . 26 7.6.1 Calcium-channel blockers . . . . 26 ESC GuidelinesPage 2 of 85 byguestonMay22,2016 3. 8. Non-surgical device treatment of heart failure with reduced ejection fraction . . . . 26 8.1 Implantable cardioverter-defibrillator . . . . 26 8.1.1 Secondary prevention of sudden cardiac death . . . . 26 8.1.2 Primary prevention of sudden cardiac death . . . . . . 27 8.2 Cardiac resynchronization therapy . . . . 28 8.3 Other implantable electrical devices . . . . 29 9. Treatment of heart failure with preserved ejection fraction . . 29 9.1 Effect of treatment on symptoms in heart failure with preserved ejection fraction . . . . 30 9.2 Effect of treatment on hospitalization for heart failure in heart failure with preserved ejection fraction . . . . 30 9.3 Effect of treatment on mortality in heart failure with preserved ejection fraction . . . . 30 9.4 Other considerations . . . .